Acadia falls after mid-stage trial setback for Alzheimer’s psychosis therapy

Acadia Pharmaceuticals reported a Phase 2 failure in Alzheimer’s disease psychosis, but the company said it saw enough signal to continue forward into Phase 3 — with a caveat. The biotech’s experimental ...

Summary from Endpoints News.

Coverage 2 articles · 2 outlets

1. Seeking Alpha Healthcare 12h ago
   Acadia falls after mid-stage trial setback for Alzheimer’s psychosis therapy ↗
2. Endpoints News 10h ago
   Acadia drug fails mid-stage study in Alzheimer's psychosis, leading to modified Phase 3 ↗